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Abstract: It has been demonstrated that tumoral cells have a higher uptake of ascorbic acid 
compared to normal cells. This differential characteristic can be used as a way to improve the 
specificity of antitumoral compounds if combined with polymeric drug delivery systems. The 
aim of this study was to prepare, characterize and evaluate the antitumoral activity of poly-
D,L-(lactide-co-glycolide) 50:50 loading the antitumoral compound violacein and capped 
with L-ascorbic acid. Nanoparticles were prepared using the nanoprecipitation method and 
morphologically characterized by scanning electron microscopy (SEM). The average diameter 
and Zeta potential were determined by photon correlation spectroscopy method (PCS), and 
assays were carried out to determine the content of ascorbic acid and in vitro drug release 
kinetics. The antitumoral activity of this system was also evaluated against HL-60 cells by 
tetrazolium reduction assay. Nanoparticles with size distribution between 300–400 nm and 
strong negative outer surface (-40 mV) were obtained by this method. Analysis of ascorbic 
acid content showed that this compound was mainly localized on the external surface of 
nanoparticles. Violacein loading efficiency was determined as 32% ± 1% and this drug was 
gradually released from nanoparticles at different rates depending on the composition of the 
release media. In addition, this system was observed to be 2 × more efficient as an antitumoral 
compared with free violacein.
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Introduction
Research on antitumoral therapies have been broadly studied in the last few years in 
order to create systems targeted to tumoral cells.1,2 In this context, differential charac-
teristics between tumoral and normal cells have been exploited as a promising way to 
improve antitumoral activities of new and currently used drugs. Some examples are 
antiangiogenic compounds,3 drugs that block activity of abnormal expressed signal-
ing proteins such as Ras and Akt,4 cytokines-based therapies,5 DNA- or protein-based 
vaccines against specific tumoral markers,6 and tyrosine-kinase inhibitors.2
Another strategy that can be employed in this context is the obtention of drug car-
riers containing antitumoral drugs and with their external surface recovered (capped) 
with a specific substrate or antibody.7 In this approach, the complex–drug vehicle can 
reach specifically tumoral cells using differential characteristics between malignant and 
normal cells as targeting marker. Such capping can be obtained by covalent binding 
of substrates to the external surface moieties of the drug carriers, self-assembly based 
on hydrophobicity or hydrophilicity, electrostatic interactions or simple deposition/
adsorption of the capping agent on the external surface of the system.International Journal of Nanomedicine 2010:5 78
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One remarkable characteristic and common to several 
tumoral lineages is their high uptake and accumulation 
of ascorbic acid due to a high expression and activity of 
glucose transporter proteins (GLUTs), which are mem-
brane or cytosolic proteins involved with internalization 
of both glucose and ascorbic acid.8 The pathway by which 
tumoral cells obtain ascorbic acid is summarized by the 
stromal oxidation mechanism, in which reactive oxygen 
species (ROS) generated by cell metabolism promote oxi-
dation of extracellular ascorbic acid to dehydroascorbate 
anion. This oxidized form is transportable via GLUTs 
and, once in the intracellular environment, the dehydro-
ascorbate anion is further reduced to ascorbic acid. Since 
the reduced form of ascorbic acid is not transportable 
through the cell membrane, this compound stays trapped 
into the cell.9 Although this characteristic gives tumoral 
cells a high resistance against oxidative stress induced by 
chemotherapeutic compounds, it can be used as a way to 
improve the specificity of drugs if combined with drug 
delivery systems.
Drug-delivery systems have been broadly studied in 
nanomedicine as a way to improve the effects of several 
drugs against different biological models.10,11 Between 
the examples already described, there are first and second 
generation liposomes,12 metallic nanoparticles,11 magnetic 
nanoparticles,13 dendrimers14,15 and polymeric nano and 
microparticles.16,17 Those systems have many advantages 
when compared with conventional drug therapies, such as 
increased bioavailability of drugs via protection of drugs 
against oxido-reduction and enzymatic reactions, improve-
ment of solubility of hydrophobic drugs in biological 
fluids, biocompatibility of matrixes and sustained release 
of compounds for long-term therapies.16 The possibility 
of capping the drug carriers with important molecules is 
also an important feature of those systems. Among the 
examples already described, there are capping of nanopar-
ticles with stealth agents to avoid capture of the system 
by phagocytes and probing molecules for diagnostic aims. 
In addition, cellular substrates or antibodies can be used 
to target the system specifically to a type of cell, thereby 
reducing harmful effects of drugs on nontargeted cells.16,18 
The combination of targeting properties of polymeric drug 
delivery systems with knowledge of differential biochemi-
cal features between normal and tumoral cells can be an 
interesting way to improve the pharmacological effects of 
already known or new antitumoral compounds.
One antitumoral compound has been isolated from 
several environmental bacteria such as Pseudoalteromonas 
luteoviolacea and Chromobacterium violaceum.19,20 This 
compound, violacein, has been shown to have several bio-
logical activities such as antitumoral, antibacterial, antiviral, 
antiparasitic, antioxidant, fungicidal and leishmanicide 
activities.20 Its antitumoral activity is marked by multitar-
get cytotoxicity mechanisms. It is known that violacein is 
a potent apoptosis inducer in leukemic HL-60 lineage by 
tumoral necrosis factor 1, caspase-8 and MAP-kinase p38 
activation.21 This drug is also capable of inducing cell death 
by generalized oxidative stress in colorectal tumoral lineage 
HT-2922 and direct enzyme modulation in lymphocytes.23 
Despite its therapeutic potential, violacein exhibits poor 
water-solubility, which restricts its use in vivo. Also, due to 
its broad spectra of biological activities, this compound has 
significant toxicity against the host. Thus, systems that allow 
to improve the hydrosolubility of violacein and to target this 
compound to a specific kind of cell can be useful to further 
exploit its pharmacological potential.
The aim of this work was the preparation, characteriza-
tion and determination of antitumoral activity of poly-D,L-
(lactide-co-glycolide) nanoparticles containing violacein and 
capped with ascorbic acid in order to improve the antitumoral 
activity of this drug. Specifically, the antitumoral activity of 
drug carriers capped with ascorbic acid and loading violacein 
as compared with the free form of violacein and its complex 
with drug carriers noncapped with ascorbic acid.
Experiment
Materials
Surfactants polyoxyethylenesorbitan monopalmitate 
(Tween  40,  M.W.  =  1,277  kDa),  polyoxyethylene-
polyoxypropylene (Pluronic F68, M.W. = 8,400 kDa), 
polymer poly-D,L-(lactide-co-glycolide) 50:50 (PLGA 
50:50, M.W. = 40,000–75,000 kDa), dimethylsulfoxide 
(DMSO), 3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetra-
zolium bromide (MTT) and antibiotics were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Violacein ([3-(1,2-
dihydro-5-(5-hydroxy-1H-indol-3-yl)-2-oxo-3H-pyrrol-3-
ilydene)-1,3-dihydro-2H-indol-2-one]) was extracted and 
purified from Chromobacterium violaceum CCT 3468, as 
previously described.24 The purity of violacein, assessed by 
nuclear magnetic resonance (NMR) and ultraviolet-visible 
spectroscopy (UV-vis), was greater than 99%. All organic 
solvents in PA grade used to extract and purify violacein were 
obtained from Synth (Sao Paulo, Brazil). Cell culture media 
RPMI 1640, heat-inactivated fetal bovine serum (FBS) and 
L-glutamine were obtained from Cultilab (Campinas, Brazil) 
and used as received.International Journal of Nanomedicine 2010:5 79
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Methods
Nanoparticles preparation
Nanoparticles were prepared by following the nanoprecipita-
tion method.25,26 Briefly, PLGA 50:50 and violacein were dis-
solved in acetone at concentrations of 1.2% and 0.5% (W/V). 
respectively. This solution was added into an aqueous phase 
containing surfactant Tween 40 and L-ascorbic acid at 1.2% 
(w/v) of each. The mixture was magnetically stirred until the 
complete evaporation of the organic solvent and centrifuged 
two times (10,000 rpm for 30 min) in Mili-Q water. The final 
pellet was freeze-dried and submitted to further analyses. Four 
groups of preparations were analyzed: NP (nanoparticles pre-
pared without violacein and without ascorbic acid), NP-AA 
(nanoparticles prepared without violacein and with ascorbic 
acid), NP-violacein (nanoparticles prepared with violacein 
and without ascorbic acid) and NP-AA-violacein (nanopar-
ticles prepared with violacein and with ascorbic acid).
characterization of nanoparticles
Average diameter and Zeta potential analysis
The average size and charge of the external surface (Zeta 
potential) were determined by photon correlation spectroscopy 
method in Mili-Q water using a Malvern ZetaSizer Nano Series 
(Malvern, United Kingdom), according to manufacturer’s 
specifications. The samples were serially diluted to avoid the 
interference of Tyndall effect in the measurements and all the 
presented data had polydispersity indexes lower than 0.05.
Morphological analysis
The final powder was submitted to morphological analysis 
using a JSM-6360LV JEOL scanning electron microscope. 
All samples were analyzed at an electron tension of 20 kV .
Drug loading efficiency and polymer recovery
Total amount of violacein (ε575 in ethanol = 3.13 × 10-2 mL.µg-1.cm-1) 
was determined by UV-Vis spectroscopy (Hitachi U-200) 
at wavelength of 575 nm.27 The particles were dispersed in 
absolute ethanol, incubated for one hour at room temperature 
to extract the violacein and centrifuged at 10,000 rpm for 
30 min to separate the drug from the reminiscent matrix. 
Polymer recovery was calculated by the expression: (total 
mass – total mass of recovered violacein)/(amount of polymer 
used in the preparation).
Ascorbic acid content analysis
To verify the final amount of ascorbic acid in the nanoparticles 
and whether this compound was localized on external surface 
of nanoparticles, the system was submitted to an ascorbic 
acid release kinetics assay. The samples were dissolved 
in phosphate-buffered saline (PBS; pH 7.4), incubated at 
200 rpm and 37 °C. At different times, the solution was 
centrifuged for five minutes at 10,000 rpm and the superna-
tant was submitted to titration by the iodimetric method28 to 
determine the amount of ascorbic acid released in the respec-
tive time. As a control for dissolution of free ascorbic acid, 
a mass of this compound in powder (equivalent to the total 
content of this substance recovered from NP-AA system) 
was put into the release solution and submitted to the same 
analyses described above. Data was normalized as percent-
age of total ascorbic acid released after an interval of time 
(amount of ascorbic acid detected in a determined time/total 
content of ascorbic acid recovered from NP-AA).
Violacein release kinetics assay
In vitro release kinetics of violacein loaded in the final powder 
was carried out in a solution of PBS and 10% Pluronic F68 
(w/v) or ethanol (v/v) at final pH of 7.4. These solutions, 
containing the nanoparticles, were incubated at 200 rpm 
and 37 °C. Periodically, the solutions were centrifuged and 
the supernatant was analyzed by UV-Vis spectroscopy at 
575 nm to determine the total amount of violacein released. 
After each measurement, 1 ml of fresh release media was 
added to the experiments to avoid violacein saturation of 
the solution. As a control, free violacein solubilization rates 
were measured. Data was normalized as percentage of total 
violacein released after an interval of time (amount of vio-
lacein detected in a determined time/total violacein loaded 
in nanoparticles).
cytotoxicity assays
cell cultures
Human promyelocytic leukemia HL-60 cells, obtained from 
the Cell Culture Collection of the Universidade Federal do 
Rio de Janeiro (UFRJ), were cultured in RPMI 1640 medium 
supplemented with 10% FBS, 100 U.mL-1 of penicillin, 
100 µg.mL-1 of streptomycin, and L-glutamine at 37 °C in a 
humidified atmosphere containing 5% CO2. Cells were used 
in the exponential growth phase at passage 15–30.
To assess cell viability, the cells were seeded (3.105 cells.mL-1) 
in 96 well plates and incubated with different concentrations of 
free or nanoparticle-loaded violacein for 72 hours, as previously 
described.29 In all experiments with encapsulated violacein, the 
final concentration of nanoparticles was maintained constant by 
addition of a complementary amount of blank. Cell viability 
was determined by MTT reduction assay and the inhibitory 
concentration for 50% of the cells (IC50) was standardized as a International Journal of Nanomedicine 2010:5 80
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toxicity measurement. Final concentrations of DMSO, needed 
to dissolve free violacein, never exceeded 0.2% (v/v). Controls 
were exposed to an equivalent concentration of DMSO and 
considered as 100% of viability.26 In order to verify whether free 
ascorbic acid has any buffering effect in free violacein-mediated 
toxicity, cells were exposed to free violacein at IC50 values and 
a concentration of ascorbic acid equivalent to the total amount 
of this compound recovered from NP-AA. Also, in line with 
previous literature,30 no decrease in the viability of HL-60 cells 
was observed when the cells were exposed to free ascorbic acid 
in concentrations below 10 µM (data not shown).
Tetrazolium reduction assay (MTT reduction)
The growth rate of HL-60 cells following treatments with free 
or encapsulated violacein was determined by MTT reduction 
assay.26 Briefly, 0.1 ml of serum-free medium containing 
MTT (1 mg.mL-1) was added to each well. After four hours 
of incubation, the supernatant was removed and the blue 
formazan product obtained was dissolved with stirring in 
0.1 ml of ethanol for 15 minutes on a microplate shaker. The 
absorbance at wavelength 570 nm was then obtained with 
a UV-vis spectrophotometer. No bleed-through effect (sum 
of absorbance values of two compounds caused by overlap-
ping absorption wavelengths) was observed in the range of 
treatment concentrations analyzed.
statistical analyses
All experiments were performed at least three times with 
four replicates. The IC50 values were calculated after 
expressing the results as a percentage of the controls and 
were determined graphically from the dose-response curves 
using the computer software package, Origin (version 6.0; 
OriginLab Corporation, Northampton, MA, USA). Prob-
abilities of P  0.05 were considered significant.
Results
Morphological analyses
The system obtained by this methodology presented a regular 
and smooth spherical shape, as observed in scanning electron 
microscopy (SEM) analyses (Figure 1). No significant dif-
ferences were observed between nanoparticles prepared with 
or without ascorbic acid (data not shown).
Drug loading efficiency and polymer 
recovery
Total loaded violacein rates for NP-violacein and NP-AA-
violacein were determined to be 32% ± 1%, while polymer 
recovery varied between 75%–78%.
Analysis of ascorbic acid content
The total content of ascorbic acid reminescent in NP-AA 
and NP-AA-violacein were determined as 1.29 ± 0.2 and 
1.31 ± 0.3 µmol per mg of particles. To further characterize 
the localization of this compound, a release kinetics assay 
was performed. As seen in Figure 2, ascorbic acid in PLGA 
nanoparticles exhibited a burst releasing behavior at five 
minutes of incubation, which is very similar to the dissolution 
profile of free ascorbic acid under the described conditions.
Average diameter and Zeta potential
By this approach, particles with a nanometric size varying 
between 300 and 550 nm and a strong negative Zeta potential 
A B
Figure 1 Scanning electron analyses of nanoparticles preparation in magnifications of 5,000 (A) and 10,000 (B) folds. No significant differences were observed among the 
four obtained systems.International Journal of Nanomedicine 2010:5 81
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were obtained (Table 1). Also, the addition of ascorbic acid 
to the preparation increased significantly the negative charge 
of the external surface by 25–30 mV .
Violacein release kinetics
No differences of the dissolution profile of free violacein in 
surfactant-buffer or ethanol-buffer solutions were observed 
(Figure 3). In terms of violacein release kinetics of nanopar-
ticles, an initial burst of release in three hours of analysis was 
observed (about 40% and 60% for surfactant-buffer and etha-
nol-buffer solutions, respectively), followed by a gradual release 
until 36 hours and reaching a cumulative release of 80% of the 
initial content at 72 hours of analysis (Figure 3). Moreover, 
a significant difference was observed in the release kinetics pro-
file of this system depending on the composition of the analysis 
solution. The release rates in ethanol-buffer media was observed 
to be faster compared to the surfactant-buffer solution.
Toxicity against hL-60 cells
The results of cytotoxicity assays of free or NP-AA-
violacein against HL-60 cells are shown in Figure 4. IC50 
values for free violacein and NP-AA-violacein were 0.5 µM 
and 0.2 µM, respectively. As a similar curve for the free 
violacein, NP-violacein showed an IC50 value of 0.4 µM 
(curve not shown). When the cells were treated with both free 
violacein and 2 µM of free ascorbic acid, a buffering effect of 
free violacein toxicity was observed, since IC50 values were 
not reached until 4.5 µM of drug exposure.
Discussion
Previous works have shown the broad spectra of biological 
activities of violacein and the multi-targeting toxicity mecha-
nism triggered by this drug,20 which reduces the rising of 
strains or cell lineages resistant to this compound. However, 
there are several hindrances to use violacein as a therapeutic 
compound. The most concerning is its poor solubility in water 
and biological fluids. For example, Lopes and colleagues31 
evaluated the antiplasmodial activity of violacein in vivo and, 
even though an elimination of 90% of a lethal Plasmodium sp. 
strain was obtained, it was not possible to completely elimi-
nate the parasite with free violacein due to its solubilization 
limit. In addition, violacein exerts toxic effects on normal 
cells. Due to this, strategies to guide this compound specifi-
cally to target cells are ongoing.
Herein, the characteristic of differential uptake of ascorbic 
acid between tumoral and normal cells was used to obtain a 
system with increased antitumoral activity. The methodology 
described here resulted in regular and smoothed shaped 
nanoparticles at a concentration of 1.2% of a nonpolymeric 
surfactant, which is the minimal amount of tensioactive 
necessary to stabilize the preparation. Using tensioactive 
concentrations lower than 1% resulted in preparations with 
poor stability and presented a rate of polymer recovery 
lower than 50% with significant macroscopic coagulation of 
polymer (data not shown). Such phenomena can be explained 
by the high ionic force of the aqueous phase of the system 
due to the high concentration of ascorbic acid used. Such 
high concentrations promote a salting-out effect on prepara-
tions with less than 1% of nonpolymeric surfactants or with 
the use of polymeric surfactants such as Pluronic F68 in the 
aqueous phase. Indeed, there was observed an incompat-
ibility of polymeric surfactants with this preparation (data 
not shown).
Evaluating the average size distribution, nanoparticles 
with two main peaks of size distribution were obtained for all 
Figure 2 Release kinetics profile of free ascorbic acid () or nanoparticles prepared 
with ascorbic acid ().
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Table 1 size distribution and Zeta potential of the obtained systems
NP NP-violacein NP-AA NP-AA-violacein
size distribution (nm)   327–410   290–487   330–576   300–400
Zeta potential (mV) -20.5 ± 5.1 -15.7 ± 2.9 -50.4 ± 3.7 -40.2 ± 4.7
Abbreviations: AA, ascorbic acid; NP, nanoparticles.International Journal of Nanomedicine 2010:5 82
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systems described as follows: 330 and 410 for NP, 290 and 
487 for NP-violacein, 330 and 576 for NP-AA, 300 and 
400 for NP-AA-violacein. This effect could be explained 
by the freeze-drying process, which promotes aggregation 
of vicinal nanoparticles. This consequently increases the 
average diameter of nanoparticle preparations and frequency 
of aggregates.32–34 However, the fact that nanoparticles with 
strong negative Zeta potential were obtained implies a better 
Figure 4 Toxicity of free or NP-AA-violacein against hL60 cells.
Notes: (■) NP-AA; () free violacein + 2 µM of ascorbic acid () free violacein; and () NP-AA-violacein.
Abbreviation: NP-AA, nanopatide-asconbic acid.
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Figure 3 Release kinetics profile free or NP-AA-violacein in ethanol-buffer ethanol-buffer (A) or surfactant-buffer (B) solutions.
Notes: () free violacein in ethanol-PBs solution; () NP-AA-violacein in ethanol-PBs solution; (■) free violacein in Tween-PBs solution () NP-AA-violacein in Tween-PBs solution.
Abbreviations: NP-AA, nanopatide-asconbic acid; PBs, Phosphate buffered saline.International Journal of Nanomedicine 2010:5 83
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stability in aqueous solution due to the electrostatic repulsion 
between particles. This facilitates the dispersion in water 
of those systems. Although nanoparticles based in PLGA 
often have a negatively charged surface as consequence 
of ionizable carboxyl-terminal moieties of this polymer, a 
significant difference was observed between particles pre-
pared with or without ascorbic acid. Since Zeta potential 
is affected by adsorption or binding of compounds to the 
external surface of colloidal particles, this difference indi-
cates the presence of a reminiscent amount of ascorbic acid 
on the external surface of the system. Ascorbic acid has two 
ionizable hydroxyl groups at carbons 3 and 4 with pKa 4.2 
and 11.6, respectively. Once the Zeta potential measurements 
were carried out at pH 7, the ionization of carbon 3 (lead-
ing to ascorbate anion formation) can explain the increased 
negative charge observed. The analysis of ascorbic acid 
content reinforces this observation since the release profile of 
ascorbic acid from the nanoparticles is marked by a massive 
release burst with five minutes of incubation. This suggests 
a weak adsorption of this compound on the external surface 
of the system.
In terms of violacein release kinetics of nanoparticles, it 
can be observed an initial burst of release at three hours of 
analysis can be observed followed by a gradual release until 
72 hours. Such behavior suggests the system has violacein 
either in its external surface or mixed with the outer surface 
of the matrix (being, therefore, easily released in short time 
incubations) and an internal content of drug that is released 
gradually, reaching a release of 80% of the initial content 
at 72 hours of analysis. Also, a significant difference in 
release rates was observed between surfactant-buffer and 
ethanol-buffer solutions, with a faster drug release rate in the 
second media. This can be explained by the difference in the 
molecular weight of both compounds since ethanol is a low 
molecular weight compound and highly diffusible through 
the polymeric matrix, allowing it to bring out the violacein 
trapped in the inner side of the nanoparticles, while the 
surfactant with high molecular weight is unable to reach the 
inner side of nanoparticles. Thus, the media surfactant-buffer 
promotes diffusion but not arrest of the drug, mimicking the 
physiological situation where the particles are surrounded by 
high molecular weight compounds such as proteins.
In cytotoxicity assays, a significant difference of activ-
ity between nanoparticles-loaded and free violacein, being 
NP-violacein and NP-AA-violacein 1.25 and 2.5 times more 
efficient than free violacein respectively was observed. 
The increased biological activity of violacein loaded in 
nanoparticles has been demonstrated in previous works 
either with tumoral cells26 or Staphylococci strains27 and the 
addition of derivatives of ascorbic acid on external surface 
of nanoparticles had been shown to increase the efficiency 
of dehydrocrotonin loaded in PLGA nanoparticles with a 
protein mediated uptake mechanism and a shunt of cell death 
mechanism to receptor-mediated pathways.29 However, an 
unexpected observation was reached, since free ascorbic acid 
exhibits a buffering effect in violacein-mediated toxicity, 
while the addition of ascorbic acid on the external surface of 
PLGA nanoparticles loading violacein actually promotes an 
improvement of the toxicity of this compound. This suggests 
a differential cell death mechanism between free violacein 
and NP-AA-violacein. Chen and colleagues35 demonstrated 
that, although ascorbic acid has mainly antioxidant proper-
ties in cell environment, it can act as a generator of reactive 
species of oxygen if it gets concentrated in the external 
tumor microenvironment. Therefore, one explanation for the 
observed fact is that the increasing in external concentration 
of ascorbic acid bound to NP-AA-violacein promotes gen-
eration of ROS in the external environment, while the high 
uptake of NP-AA-violacein complex promotes significant 
internal oxidative damage, leading to internal and external 
cell damage. Since ROS are necessary to promote the inter-
nalization of ascorbic acid, a positive feedback mechanism 
of internalization of NP-AA-violacein could be involved 
in the increased toxicity observed. Further studies should 
provide insights about the death mechanism triggered by 
the presented system.
Current drug delivery systems targeted to tumoral cells 
often use either peptides or proteins, such as transferrin and 
epithelial growth factor receptor (EGFR), or small molecules 
such as folate.16,36 All the cited molecules have been used 
in vitro or in vivo with promising results and high specificity. 
However, the efficiency of targeting depends on the lineage 
analyzed, since uptake of tranferrin, EGFR and folate broadly 
varies between tumoral cells. Specifically, transferrin and 
EGFR are useful for solid tumors,36 whereas folate can be 
used for both solid and nonsolid tumors. It has been shown that 
uptake of folate-targeted drug delivery systems is decreased in 
tumoral models which have lower density of folate receptors, 
such as HeLa and MCF-7 cells.37 Thus, the spectra of uses of 
those molecules are restricted depending on the cell model 
studied. On the other hand, the role of ascorbic acid in cancer 
metabolism is well described for several tumoral lineages and 
its high uptake is a characteristic common to most solid or 
nonsolid tumors analyzed,38–40 which makes it an interesting 
molecule to target a broader spectra of tumors. In addition, 
it has been reported that overexpression of GLUT proteins International Journal of Nanomedicine 2010:5 84
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is a marker of very aggressive hepatocellular carcinomas.41 
In this context, the proposed system can be used to target 
drugs with multi-toxicity mechanisms to tumors refractory 
to current chemotherapies.
Although ascorbic acid is a molecule susceptible to 
oxidation, the oxidized form of this molecule (dehydro-
ascorbate anion) can also target drug carriers, since the 
internalization of ascorbic acid requires its oxidation to dehy-
droascorbate by cellular ROS. However, efforts to create drug 
carriers with derivatives of ascorbic acid to avoid undesirable 
oxidation processes and to improve the shelf-life of ascorbic 
acid on nanoparticles are being carried out and showed prom-
ising results with polymeric nanoparticles carrying another 
antitumoral compound, dehydrocrotonin.29 Complementary 
studies on toxicity of such complexes against normal cells and 
in vivo evaluations should be carried out to further character-
ize the pharmacological potential of this system.
Conclusions
The presented system could successfully load violacein and 
be capped with ascorbic acid, with good physical-chemical 
parameters of stability and a significant improvement of anti-
tumoral activity of the complex. No buffering or antagonist 
effects on violacein activity were observed when ascorbic 
acid was used as a capping agent in the system. However, 
further characterization of the cell mechanism induced by this 
system and in vivo assays should be carried out. This prepa-
ration could be used as a selective way to administer higher 
doses of violacein in vitro and in vivo in order to improve its 
biological activity and to reduce side effects.
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